Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDOMINACE: Dapagliflozin to prevent early ventricular dysfunction after acute anterior STEMI
ChiCTR2100048157Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dapagliflozin in myocardial infarction (MI) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: NT-pro-BNP level. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2100048157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048157.